Pharma

The gap

• Measurements in clinical trials are often subjective, imprecise, lack repeatability and deliver poor statistical quality of results
  
• Do not have good and early indicators of safety and efficacy
• Difficult to successfully develop new drugs when the cohort is based on patients where the disease has already progressed beyond where the drugs can have an impact
• No ability to monitor "in real-time" the effect on each trial participant
• Difficult to measure cognitive side effects of their drugs
• In neurology and psychiatry, diagnosis is often incorrect
• Clinical trials are often very demanding on the subjects, including multiple visits to the clinic
  

NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry

• ​​​​​​​Much more sensitive and less variable indicators of disease state and efficacy in drug trials
• Objective measures of disease state, disease progression and response to therapy
• NeuraMetrix have developed fingerprint for each disease, which the diagnosis can be compared to
• Ability to identify patient segmentation strategies
• Granular quantification of disease symptoms
• Very automated system, with easy to use interfaces
• Almost no burden on the patient - all in the background and no tests

• Deploy smaller, faster clinical trials
• Get early warning signals of whether trial will be successful or not
• Micromanage the set of subjects, dependent on the response to treat
• Change the sample size of the trial very quickly, dependent on the result to date
• Verify that a subject's diagnosis is correct
• Increase prognostic enrichment: selection of patients at high risk of disease-related endpoints
• Increase predictive enrichment: selection of patients sub segment with disease stages more likely to drug treatment 
• Have trials designs which include pre-randomization baseline "run-in" period to exclude patients whose symptoms resolve spontaneously or have highly variable baseline symptoms
• Identify patients likely to adhere to treatment or other variables
• Identify responders vs. non-responders by quantifying patient symptoms and track longitudinally  
• Make it easier for the cohort
  

• Faster go/no go decisions
  
• Decreased variability
  
• Decreased heterogeneity
• Increased study power
• Better management of drug trials
• Fewer participants dropping out of drug trials 
• Less risk
• Less cost